ARCHIVES

Phase III Xilonix Study Halted Following Unscheduled Analysis

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: David Harrington Replaces Zelen At ECOG; Kushnet To Receive Ewing Layman’s Award

December 1, 1989

Avastin Loses Indication for Breast Cancer

November 18, 2011

Pazdur Waxes On Calumet City And Krebiozen; Parkinson Takes Interim CMO Job at Zyngenia

April 27, 2012

Sales of Smoking Cessation Aids Increase, Effectiveness Drops

October 25, 2002

Aflibercept-Docetaxel Combination Misses Primary Survival Endpoint

March 25, 2011

CPRIT Likely to Get Funding For Two Years; DePinho Announces Austerity Measures

May 17, 2013